See Beyond the Expected.
Our team’s mission and vision for earlier detection of Leptomeningeal Metastases
At CNSide® Diagnostics, LLC, our company’s Mission is to revolutionize the clinical management of patients with Leptomeningeal Metastases (LM) through innovative diagnostic solutions.
Our company’s Vision is to improve patient outcomes by delivering cutting-edge diagnostics that enable personalized and effective treatment strategies.
Leadership Team
Russell Bradley
President & General Manager
Marc Hedrick, MD, MBA
President & CEO, Plus Therapeutics
Russ Havranek, MS, MBA
EVP, Commercial & Corporate Strategy
Jonathan Stein, PhD, HCLD(ABB)
Laboratory Director
Andrew Brenner, MD, PhD
Ad-Interim CMO
Andrew Sims, CPA
CFO & VP of Finance
Consolidated Clinical Laboratory & Manufacturing Facility in Houston, Texas
Full vertical integration in single facility
- Centrally located in the U.S. for efficient shipping and logistics
- Includes on-site advanced imaging, molecular analysis, cell-handling
- In-house manufacturing of key test components with ability to scale:
- CEE-Sure® CSF collection tube preservative
- Antibody mix
- Microfluidic chip
- Licensed with the Clinical Laboratory Improvement Amendments (CLIA) from the Centers for Medicare and Medicaid Services (CMS): CLIA Certificate of Accreditation 45D2308861
- Lab Director: Jonathan Stein, PhD, HCLD (ABB)
Our History
The CNSide® Cerebrospinal Fluid (CSF) Assay Platform was originally developed as a more sensitive and informative method for detecting and analyzing cancer cells in CSF compared to traditional CSF cytology.
CNSide® was initially launched in the U.S. by another company as a commercial assay in 2020. In 2022 and 2023, Plus Therapeutics partnered with and licensed the CNSide® technology from that company to support its own ReSPECT-LM clinical trials and development of the REYOBIQ targeted radiotherapeutic drug candidate for Leptomeningeal Metastases (LM). Plus Therapeutics acquired all CNSide® assets and established a new subsidiary, CNSide® Diagnostics, LLC, in 2024. The company is now focused on commercializing the CNSide® CSF Assay Platform in the U.S., starting with the Tumor Cell Enumeration (TCE) test.